Edwards Lifesciences (Edwards Lifesciences) Cash And Cash Equivalents

: $1,144 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Edwards Lifesciences's quarterly cash and cash equivalents increased from Jun. 2023 ($1,042.60 Mil) to Sep. 2023 ($1,410.10 Mil) but then stayed the same from Sep. 2023 ($1,410.10 Mil) to Dec. 2023 ($1,144.00 Mil).

Edwards Lifesciences's annual cash and cash equivalents declined from Dec. 2021 ($862.80 Mil) to Dec. 2022 ($769.00 Mil) but then increased from Dec. 2022 ($769.00 Mil) to Dec. 2023 ($1,144.00 Mil).

Edwards Lifesciences Cash And Cash Equivalents Historical Data

The historical data trend for Edwards Lifesciences's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edwards Lifesciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

1,179.10

1,183.20

862.80

769.00

1,144.00

Edwards Lifesciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents																769.00	872.50	1,042.60	1,410.10	1,144.00

Edwards Lifesciences Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Edwards Lifesciences (NYSE:EW) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Edwards Lifesciences Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Edwards Lifesciences's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Edwards Lifesciences (Edwards Lifesciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (NYSE:EW) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

EW:Mexico 1EW:Italy EWL:Germany EWL:Germany EWL:Germany E1WL34:Brazil EWLS:Austria

Address

One Edwards Way, Irvine, CA, USA, 92614

Website

https://www.edwards.com

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.

Executives

Bobo Donald E Jr	officer: CVP,Strategy/Corp Development	C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE CA 92614
Michael A Mussallem	director, officer: Chairman & CEO	C/O EDWARDS LIFESCIENCES CORP, ONE EDWARDS WAY, IRVINE CA 92614
Scott B. Ullem	officer: CVP, CFO	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Daveen Chopra	officer: CVP, Surgical Structural Heart	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92618
Larry L Wood	officer: CVP, THV Replacement	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Catherine M. Szyman	officer: CVP, Critical Care	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Wayne Markowitz	officer: GM & SVP, Surgical	ONE EDWARDS WAY, IRVINE CA 92614
Heisz Leslie Stone	director	C/O PUBLIC STORAGE, 701 WESTERN AVENUE, GLENDALE CA 91201
Jean-luc M Lemercier	officer: CVP, EMEA, Canada, Latin Amer	C/O ONE EDWARDS WAY, IRVINE CA 92614
Sellers Robert W.a.	officer: VP, Corp. Controller (Principa	ONE EDWARDS WAY, IRVINE CA 92614
Bernard J Zovighian	officer: CVP, Surgical Heart Valves	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Huimin Wang	officer: CVP, Japan & Intercontinental	C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE CA 92614
Martha H. Marsh	director	9769 WEXFORD CIRCLE, GRANITE BAY CA 95746
Kieran Gallahue	director	PO BOX 684369, PARK CITY UT 84068
Nicholas J Valeriani	director	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614